Medical device company Mainstay Medical has said that Jason Hannon will succeed Peter Crosby as its chief executive officer with effect from next month.
Mr Hannon most recently served as President and COO of NuVasive, a medical device company focused on transforming spine surgery with minimally disruptive solutions.
Mainstay Medical also today reported revenues of $0.25m for the six months to the end of June.
The company's operating expenses rose to $12.3m from $8m the same time last year.
It said the increase was due to to the ramp up of enrolments and implants in its ReActiv8-B trial, and expenditure arising on sales activities, which started this year.
The company, which is quoted on the Irish Stock Exchange, is looking to bring to market its ReActiv8-B system, which treats chronic back pain.
The company's outgoing CEO Peter Crosby said the ReActiv8-B clinical trial is a key step towards commercialisation in the US, its most significant target market.
"The trial is advancing well, and the enrolment rate has been accelerating as the number of active sites increased during 2017, and based on our experience to date, we anticipate enrolment will complete around the end of 2017, with results available in 2018," Mr Crosby said.
The company has also begun commercialisation of ReActiv8 in Europe.
"Following the first sale and implant in early 2017, our initial customers are gaining experience with ReActiv8 and we are working with them to help integrate it into their clinical routine," Mr Crosby said.
"We continue to advance our strategy of targeting key reference centres in Germany, and then building on that experience and data from the ReActiv8-B Trial to expand commercialisation to additional centres and other countries," he added.
